The venue for this event is The Royal College of Pathologists
2 Carlton House Terrace is the home of the Royal College of Pathologists, a professional membership organisation, concerned with all matters relating to the science and practice of pathology.
Carlton House Terrace was constructed largely between 1826 and 1829 and it remains the property of the Queen. Its balconies overlook the Mall in central London where Buckingham palace stands.
This is a Euroscicon Small Conference, an outline of the day can be found at
This meeting sets out to bring researchers together to discuss the latest developments in the rapidly expanding field of Tissue Engineering and Regenerative Medicine
This event has CPD accreditation
This event is part of the 2013 Euroscicon Stem Cell Trilogy. To find out more see www.stemcells2013.com
Meeting chair: Dr Paolo De Coppi, MD, PhD, Senior Lecturer and Consultant Paediatric Surgeon, Head of the Surgery Unit, UCL Institute of Child Health and Great Ormond Street Hospital, London, UK
9:00 – 9:30 Registration
9:30 – 10:00 Introduction by the Chair: Dr Paolo De Coppi, MD, PhD, Senior Lecturer and Consultant Paediatric Surgeon, Head of the Surgery Unit, UCL Institute of Child Health and Great Ormond Street Hospital, London, UK
Congenital malformation and regenerative medicine: moving towards therapy
The number of neonates born with congenital malformations is increasing. The correction of congenital malformations has not significantly changed during the last 10-20 years and complex and often multiple operations still represent the only practical solution. The current approach to treatment of birth defects and various diseases is to modify the defective organs or to replace them with artificial substitutes or organ transplant. Stem cells can be derived from human amniotic fluid, which could be collected safely at prenatal diagnosis. Evidence provided in the last few years, suggests that they can harbour a therapeutic potential for human diseases, as amniotic fluid stem (AFS) cells have been isolated. AFS cells have intermediate characteristics between embryonic and adult stem cells. C-Kit(+)Lin(-) cells derived from amniotic fluid displayed a multilineage hematopoietic potential and they can be easily reprogrammed to a pluripotent status. With the aim of engineering functional organs, AFS cells have been seeded into decellularised organs and could represent in the future an alternative therapy for congenital malformations.
10:00 – 10:30 Steps towards Physiological simulation of Dental Tissues
Dr Reem El-Gendy, Leeds Dental Institute
10:30 – 10:40 TISSUE ENGINEERED BONE GRAFTS BASED ON BIOMIMETIC NANOCOMPOSITE PLGA/AMORPHOUS CALCIUM PHOSPHATE SCAFFOLD AND HUMAN ADIPOSE-DERIVED STEM CELLS
Dr. Johanna Buschmann, Division of Plastic and Hand Surgery, University Hospital Zurich, Sternwartstrasse 14, CH-8091 Zurich, Switzerland
10: 40 – 10: 50 MesoRex PROCEDURE USING AN AUTOLOGOUS STEM CELL DERIVED VEIN
VK.Kuna, Laboratory for Transplantation and Regenerative Medicine, Sahlgrenska Science Park, Medicinaregatan 8B, S41346, Gothenburg, Sweden.
10:50 – 11:10 Speakers’ photo then mid-morning break and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:10 – 11:20 CLINICAL TRANSPLANTATION OF A TISSUE-ENGINEERED HUMAN TRACHEA WITH AUTOLOGOUS STEM CELLS: PREPARATION, TRANSPLANTATION AND HISTOPATHOLOGICAL REPORT
Nikhil Nayakwad Laboratory for Transplantation and Regenerative Medicine, Sahlgrenska Science Park, Medicinaregatan 8A, 2nd floor, 413 46 Göteborg, Sweden.
11:20 – 11:30 TISSUE ENGINEERING OF HUMAN SMALL INTESTINE USING BONE MARROW STEM CELLS
PB Patil, Laboratory for Transplantation and Regenerative Medicine, Sahlgrenska Science Park, Medicinaregatan 8B, S41346, Gothenburg, Sweden.
11:30 – 12:00 Immunocompetent models of human respiratory epithelium
Dr Amir Ghaem-Maghami, Nottingham University
Despite enhanced patient care, the morbidity and mortality of patients with lung disease have remained high. This is partly due to lack of efficient therapeutic strategies and also that a large proportion of patients do not respond to treatments. There is a lack of predictive preclinical models of asthma and new treatments that enter clinical trials frequently fail, possibly because preclinical animal studies are often limited in their physiological relevance to the human lung. To address some of these issues we are developing a physiologically relevant immune responsive 3D model of human lung that can be used for drug assessment and disease modelling.
12:00 – 12:30 Bone regenerating ceramic materials
Professor Joost de Bruijn, Professor of Biomaterials, School of Engineering and Materials Science, QMUL, UK
The use of growth factors or progenitor/stem cells for functional bone tissue regeneration have received much attention as potential alternatives to autologous bone grafting in the past decades. Some of the hurdles to overcome in these technologies include ensuring cell survival with the cell therapy approach and using potent but less supra-physiological concentrations of growth factors to minimize adverse reactions. To circumvent the necessity of cells or growth factors in bone tissue regeneration, we have developed a micro/nanostructured calcium phosphate ceramic that is capable of inducing bone formation without the necessity of adding cells or growth factors. These osteoinductive ceramics have shown excellent bone regeneration potential of large, critical sized bone defects. In this talk, an overview will be provided of the research performed in various pre-clinical and clinical case studies on this new group of bone regenerating ceramics.
12:30 – 13:30 Lunch and trade show
13:30 – 14:30 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day
14:30 – 15:00 Seeing around the corner at future strategies in corneal regeneration
Dr Andrew Hopkinson, Queen's Medical Centre, Nottingham, United Kingdom
15:00– 15:30 Afternoon Tea/Coffee and trade show
15:30 - 16:00 3-Dimensional Culture Models of Joint Tissues: Applications in Tissue Engineering and Arthritis Research
Dr Ali Mobasheri, Associate Professor and Reader in Comparative Physiology, University of Nottingham, UK
This presentation will focus on some of the most popular in vitro models that have been developed for cartilage tissue engineering. Many in vitro models can be used as drug screening systems and as culture models for studying the biology of cartilage and the pathophysiology of joint disease. This presentation will also highlight the fact that regenerative medicine and tissue engineering have important consequences for animal research and can be exploited to develop powerful animal sparing in vitro models. Refining these models will advance tissue engineering and regenerative medicine and may significantly reduce our dependence on animals in research.
16: 00 - 16:30 Novel Biomaterials for use in Regenerative Medicine
Professor Sandra Downes, Manchester University, UK
The development of novel biomaterials for regenerative medicine will be examined. The opportunities and challenges will be discussed. The processes involved in translational research will be considered in the context of a number of applications including peripheral nerve repair and bone repair. The concept of cell therapy in two major clinical applications, namely: Ageing Macular Degeneration (AMD) and Diabetes Type 1. Recent scientific results will be presented, including Materials Chemistry, Biomechanics and in vitro cell Biology.
16:30 – 17:00 Cadaver Bone Marrow Mesenchymal Stem Cells for the Treatment of Large Burns
Professor Eduardo Mansilla, Director Tissue Engineering, Regenerative Medicine and Cell Therapies Laboratory CUCAIBA Province of Buenos Aires, Ministry of Health, La Plata, Argentina
Professor of Internal Medicine, School of Medical Sciences, National University of La Plata, Argentina
Cadaver Stem Cells (CSCs), will probably be generating soon a profound research activity in Regenerative Medicine and Transplantation. Maybe also, a real scientific revolution in these fields. As far as we know, we have been the first ones in the world, to use Cadaveric Bone Marrow MSCs to treat large severe burns, in a human clinical trial. We are really confident and see feasibility as well as a great potential for the routine salvage and therapeutic use of CSCs in the near future. If this comes to be true, it might surely significantly change the way we see today the possible sources of stem cells obtention. In this way, we might be finally considering CSCs as very important tools for many and different cell therapies including large burns.
17:00 Chairman’s summing up
Dont forget to sign up to Euroscicons’ e-newsletter at www.euroscicon.com/signup.htm to keep up to date with European Life Science news and events and to be notified of the follow up to this event
This meeting was organised by Euroscicon (www.euroscicon.com), a team of dedicated professionals working for the continuous improvement of technical knowledge transfer to all scientists. Euroscicon believe that they can make a positive difference to the quality of science by providing cutting edge information on new technological advancements to the scientific community. This is provided via our exceptional services to individual scientists, research institutions and industry.
Key words: arthritis, stem cell, tissue engineering, periodontal ligament, in situ models, Articular cartilage; osteoarthritis; tissue engineering; regenerative medicine; 3-dimensional culture, Bone graft, biomaterial, surface structure, osteoinduction, lung, epithelia cells, dendritic cells, respiratory diseases, Polymers, Regenerative Medicine, Cell Therapy, Nerve, Bone, Regeneration. Burns. Cadaver Mesenchymal Stem Cells, Corneal regeneration, amniotic membrane, tissue engineering, mesehnchymal stem cells,
About the Chair
Paolo De Coppi is the Head of the Surgery Unit and Consultant Paediatric Surgeon at the Great Ormond Street Hospital for Children and the UCL Institute of Child Health (since 2006). Concomitantly he is an Adjunct Assistant Professor at the Wake Forest Institute for Regenerative Medicine, Wake Forest University, Wiston-Salem, NC, US (since 2009) and Honorary Assistant Professor Paediatric Surgery, University of Padua, Italy (since 2005).
He has a special interest in congenital malformation and their treatment using minimally invasive techniques. He has focused his research interests on stem cells and tissue engineering, trying to find new modalities for the treatment of complex congenital anomalies. While working with Dr A. Atala at the Childrens’ Hospital in Boston-US, he had the opportunity of identifying a new source of cells for therapeutic applications showing the possibility of using stem cells from amniotic fluid. This finding generated an international patent, the cover of the January 2007 issue of Nature Biotechnology, and it has opened the development of new ways for the correction of congenital malformations. More recently, his team has demonstrated that these cells are able to differentiate into various tissues and to replace functional activity in animal model of diseases. He is now focused on developing reliable methods for stem cell isolation, expansion and differentiation at clinical level (GMP-grade). Finally, in 2010 he was part of the team, which performed the first successful transplantation of a tissue-engineered trachea on a child at the Great Ormond Street Hospital.
He has published more than 100 peer-reviewed articles in high-impact factor journals such as The Lancet, Nature Biotechnology, Blood and FasebJ; supervised more than 25 research fellow and PhD students and holds various National and International grants. Since 2009 he has joined the Editorial Board of Pediatric Surgery International, Stem Cell Development and Fetal and Maternal Medicine Review; since 2011 he has also become Associate Editor for Stem Cell Translational Medicine.
About the Speakers
Ali Mobasheri is an Associate Professor and Reader at the University of Nottingham. He currently serves on the University of Nottingham's Ethical Review Committee (ERC) and the EU strategy group which will develop the University's strategic approach to European Funding and in particular Horizon 2020. He has a strong background in cartilage biology in the context of ageing, inflammation and disease. He is the co-ordinator of the EU FP7 funded D-BOARD consortium, which brings together leading European academic institutions and SMEs to focus on the identification, validation and qualification of new biomarkers for degenerative and inflammatory diseases of joints.
Eduardo Mansilla: Director Tissue Engineering, Regenerative Medicine and Cell Therapies Laboratory CUCAIBA Province of Buenos Aires, Ministry of Health, La Plata, Argentina
Sandra Downes (The University of Manchester) has worked in the field of Biomaterials for more than 20 years in both the Academic and the Industrial environment. Her contributions to the field include publications and studies of cellular interactions with biomaterials, biopolymers, tissue repair, biocompatibility, novel polymers and composite materials. She has a strong interest in designing biomaterials that mimic the structures of tissues. Her expertise and experience span the fields of Biochemistry, Physiology, Cell/Molecular Biology, Chemistry, Biomechanics and in vivo Biology. She holds patents for novel medical devices in tendon, peripheral nerve and bone repair.
Andrew Hopkinson attained his PhD at the University of Nottingham, studying the healing properties of amniotic membrane as an ophthalmic biological bandage. His post doctorate studies involved investigating amniotic membrane as a tissue engineering substrate, and limbal and mesenchyme stem cells with the aim of developing corneal mimetic constructs. Since then he has established himself as a principal investigator in ophthalmic regenerative medicine, in the Division of Ophthalmology and Visual, Nottingham, researching innovative stem cell and tissue engineering technologies for the development of future therapies for corneal regeneration. His currently directs pre-clinical evaluation and clinical translation of innovate regenerative therapies
Amir Ghaem Maghami obtained his MD prior to studying for a PhD in Immunology at the University of Nottingham. Prior to his appointment as a lecturer in Immunology he worked as a research fellow in Leicester and Nottingham Universities, investigating the role of antigen presenting cells in infectious and allergic diseases. He is currently an Associate Professor (Faculty of Medicine, University of Nottingham) and leads the Allergy and Tissue Modelling Research Group. For many years he has been investigating the innate properties of allergens and early events at the interface of allergens and the immune system that lead to T cell polarisation. More recently his research has focused on using tissue engineering approaches for developing immunocompetent human tissue models as platforms for testing new drugs and disease modelling.
Joost D de Bruijn (1966) holds the Chair of Biomaterials at Queen Mary University of London, United Kingdom and is Professor of Regenerative Medicine and Entrepreneurship at Twente University, The Netherlands. His current research focuses on tissue instructive materials (bone, cartilage) and mesenchymal stem cells. Prof de Bruijn is also founder and CEO of the Dutch biotech start-ups Xpand Biotechnology BV and Progentix Orthobiology BV that focus on stem cell expansion bioreactor technology and bone inducing ceramic materials. To date, he has published 135 papers in peer-reviewed journals and is inventor of 28 international patents
Event Web Site: www.regonline.co.uk/Regen2013
Phone: 07507 799380
For accommodation and travel please contact email@example.com
For enquiries regarding payment email: firstname.lastname@example.org
You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
Payment must be received prior to the meeting
You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process). After registration you will be emailed details of where to send your cheque.
Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly
Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration. After registration you will be emailed details of where transfer your money.
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"
EuroSciCon Ltd. Registered in England and Wales,
Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5